Alphavedic pivoted from healthtech to ayurvedic D2C and turned profitable without funding
A Mumbai ayurvedic startup quit its niche telehealth model in 2020, bet on B2B corporate gifting, and turned profitable on INR 5.5 Cr of FY23 revenue.
What was changed
Shrey Jain founded Alphavedic in Mumbai in 2019 as an ayurvedic healthtech startup connecting patients with ayurvedic doctors. The platform took off at first, but Jain found the niche too small: ayurvedic treatment is not mainstream. Shruti Khare joined as co-founder in 2019, and after months of deliberation the pair pivoted in 2020 to a pure-play ayurvedic products company, starting with a haircare line.
Distribution was built without ad spend. Jain used influencers on a collaboration basis — no monetary agreements, he told Inc42 — then let incoming customer queries shape the product line. The decisive bet was B2B: corporate gifting and similar engagements now bring in almost 70% of revenue, alongside sales through its own site and Amazon, Nykaa and Flipkart, and about 10% from 40 offline chains such as salons, resorts and hotels.
Alphavedic reports INR 5.5 Cr of revenue for FY23 with roughly 26% of it as gross profit, 50,000 customers of whom 40% reorder, and positive cash flow helped by a flat 60-day credit agreement with its contract manufacturers. It targets INR 8 Cr for FY24 and is seeking $2–2.5M of outside funding after four fully bootstrapped years.
Why it worked
Inc42 data: only 30% of unicorns in the D2C space were even barely profitable in FY22 — the paid-growth playbook usually burns cash.
Corporate gifting concentrates demand: B2B orders reach many end users without per-customer acquisition spending.
Influencer collaborations without monetary contracts kept marketing spend near zero from day one.
A flat 60-day credit agreement with vendors kept cash positive, so profitability did not depend on working-capital infusions.
What can be applied
When the service is too niche, sell the products the service implied — and let one corporate gifting buyer replace hundreds of paid acquisitions.
Aftermath
Alphavedic plans INR 8 Cr of FY24 revenue on an expanded portfolio and wants to grow from 40 to 100 offline chains. It remains an outlier among bootstrapped peers: ayurvedic rivals with far more revenue, such as The Ayurveda Co (INR 50 Cr net revenue in FY23, targeting INR 150 Cr in FY24), are still loss-making, and Inc42 notes most funded D2C beauty brands run losses. The company is now looking to raise $2–2.5M to accelerate.